March 14, 2017

Solid Honors Rare Disease Day 2017

Solid Biosciences is proud to join the global Rare Disease community to recognize Rare Disease Day 2017. Sponsored by EURORDIS on the last day of February each year, Rare Disease Day raises awareness amongst the general public and decision-makers about rare diseases and their impact on patients' lives.

In our mission to end Duchenne muscular dystrophy, we understand how important it is to work together with the entire Rare Disease community – researchers, fellow companies, government and families – to bring forward new innovations and effect true change.

This year, we were honored to participate in the conversation in several ways, including attending MassBio’s Rare Disease Day 2017 Massachusetts State House event and the Jett Foundation’s 2nd annual Rare Disease luncheon. In addition, our team sported their best jeans to support the Global Gene’s Wear That Your Care® campaign.

Related news


Synpromics Ltd, the leader in gene control, today announces a new research partnership with Solid Biosciences, LLC. 


New data from the SGT-001 preclinical program was published today in Molecular Therapy – Methods and Clinical Development

  • Jennifer Ziolkowski, CPA, joins as Chief Financial Officer.
  • Carl Morris, Ph.D., promoted to Chief Scientific Officer.
  • Joel Schneider, Ph.D., promoted to Chief Technology Officer, Head of Exploratory R&D.

Company to Use Proceeds to Advance Programs for Duchenne Muscular Dystrophy.


As we move into 2017, I want to reflect on our journey since founding Solid three years ago and to outline what we hope to accomplish in the coming year.


It has been an exciting and emotional time for our Duchenne muscular dystrophy (DMD) community.


Solid Biosciences congratulates Sarepta on the U.S. approval of the first therapy for Duchenne muscular dystrophy.


Solid Biosciences joined the Jett Foundation and other members of the local Cambridge, MA community to observe World Duchenne Awareness Day.


Solid Biosciences Community Update Q2 2016


Grants from the charities Duchenne Now, Save Our Sons and Fight DMD will support important work in furthering Solid’s gene therapy and disease modifying therapy programs.


More information about Solid?

Please subscribe to receive our latest news